Learn About Mycosis Fungoides

What is the definition of Mycosis Fungoides?

Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified.

What are the causes of Mycosis Fungoides?

The cause of mycosis fungoides is unknown. Most affected individuals have one or more chromosomal abnormalities, such as the loss or gain of genetic material. These abnormalities occur during a person's lifetime and are found only in the DNA of cancerous cells. Abnormalities have been found on most chromosomes, but some regions are more commonly affected than others. People with this condition tend to have additions of DNA in regions of chromosomes 7 and 17 or loss of DNA from regions of chromosomes 9 and 10. It is unclear whether these genetic changes play a role in mycosis fungoides, although the tendency to acquire chromosome abnormalities (chromosomal instability) is a feature of many cancers. It can lead to genetic changes that allow cells to grow and divide uncontrollably.

How prevalent is Mycosis Fungoides?

Mycosis fungoides occurs in about 1 in 100,000 to 350,000 individuals. It accounts for approximately 70 percent of cutaneous T-cell lymphomas. For unknown reasons, mycosis fungoides affects males nearly twice as often as females. In the United States, there are an estimated 3.6 cases per million people each year. The condition has been found in regions around the world.

Is Mycosis Fungoides an inherited disorder?

The inheritance pattern of mycosis fungoides has not been determined. Although the condition has been found in multiple members of more than a dozen families, it most often occurs in people with no history of the disorder in their family and is typically not inherited.

Who are the top Mycosis Fungoides Local Doctors?
Experienced in Mycosis Fungoides
Hematology Oncology | Oncology | Hematology
Experienced in Mycosis Fungoides
Hematology Oncology | Oncology | Hematology

Wentworth Douglass Physician Corporation

789 Central Ave, 
Dover, NH 
 (9.4 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Christine Wasilewski is a Hematologist Oncology specialist and an Oncologist in Dover, New Hampshire. Dr. Wasilewski and is rated as an Experienced provider by MediFind in the treatment of Mycosis Fungoides. Her top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Multiple Myeloma, and Angiosarcoma. Dr. Wasilewski is currently accepting new patients.

Advanced in Mycosis Fungoides
Advanced in Mycosis Fungoides

NEDA Skin Solutions - Exeter

23 Hampton Rd., 
Exeter, NH 
 (11.4 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Kaila Sinclair is a Dermatologist in Exeter, New Hampshire. Dr. Sinclair and is rated as an Advanced provider by MediFind in the treatment of Mycosis Fungoides. Her top areas of expertise are Neurocutaneous Melanosis, Familial Atypical Multiple Mole Melanoma Syndrome, Giant Congenital Nevus, and Giant Congenital Melanocytic Nevus. Dr. Sinclair is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Mycosis Fungoides
Advanced in Mycosis Fungoides

NEDA Skin Solutions - Portsmouth

155 Borthwick Avenue, Suite 201 West, 
Portsmouth, NH 
 (11.7 mi)
Languages Spoken:
English, Spanish
Accepting New Patients
Offers Telehealth

Christine Kannler is a Dermatologist in Portsmouth, New Hampshire. Dr. Kannler and is rated as an Advanced provider by MediFind in the treatment of Mycosis Fungoides. His top areas of expertise are Liver Spots, Universal Acquired Melanosis, Giant Congenital Nevus, and Giant Congenital Melanocytic Nevus. Dr. Kannler is currently accepting new patients.

What are the latest Mycosis Fungoides Clinical Trials?
Phase I Study With an Expansion Cohort of Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome

Summary: The hypotheses of this study are that single agent CPI-0209 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, CPI-0209 will demonstrate efficacy and be worth of further study.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL

Summary: This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with ...

Who are the sources who wrote this article ?

Published Date: May 17, 2021
Published By: National Institutes of Health